Psychedelic News and Analysis Made Simple for Investors

Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.

Track the entire psychedelic market

Track the entire psychedelic market

We’ve developed the first all encompassing index to track the public psychedelic marketplace.

Explore the Index

Just Some of the Data we Cover

Latest News

Press

Algernon to Acquire NoBrainer Imaging Centers, Inc. – Plans to Establish Alzheimer’s Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology

VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has entered into share exchange agreements to acquire 100% of the issued and outstanding shares of NoBrainer Imaging Centers, Inc. (“NIC”) (the “Transaction”). The…

Atai Press

Atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

NEW YORK and BERLIN, May 13, 2025 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that the first patient has been dosed in the exploratory Phase 2 study of EMP-01 (R-3,4-methylenedioxy-methamphetamine (R-MDMA)) for the…

Revive Therapeautics Press

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

TORONTO, May 12, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent…

Press

SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

TEL AVIV, Israel, May 12, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has led to the publication…

Optimi-Health Press

Optimi Health Corp. Obtains U.S. FDA Drug Establishment Registration

Optimi Health Corp. has received its U.S. FDA Establishment Identifier number-a key regulatory step for engaging in FDA filings and compliant supply into the United States. With this designation, Optimi is formally recognized within the U.S. FDA system for the manufacture of pharmaceutical-grade MDMA and psilocybin, including both active ingredients and finished drug products. Supported…

Press Release Press

Neural Therapeutics Announces SERFOR Permit Renewal Submission and Extension of LOI with HANF.COM

Toronto, Ontario–(Newsfile Corp. – May 9, 2025) – Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) (“Neural” or the “Company“), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that it has submitted a renewal application to Servicio Nacional Forestal y de Fauna Silvestre…

Filament Health Press

Filament Health Announces First Quarter 2025 Financial Results and Operational Highlights

VANCOUVER, BC, May 8, 2025 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (CBOE: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, released its first quarter financial results and operational highlights for the period ended March 31, 2025. “This quarter we were pleased to see positive data from a clinical trial studying our botanical psilocybin…

Explore the Psychedelic Landscape

Learn more about the psychedelic companies changing the industry.